# OnCo record iparomlimab-tuvonralimab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/iparomlimab-tuvonralimab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "iparomlimab-tuvonralimab" ;
  schema:name "Iparomlimab and tuvonralimab"@en ;
  schema:alternateName "PSB205"@en ;
  schema:description "QL1706 is Qilu Pharmaceutical's PD-1 plus CTLA-4 antibody mixture, approved in China in 2024 for recurrent or metastatic cervical cancer after platinum chemotherapy."@en ;
  schema:url <https://onco.cc/drugs/iparomlimab-tuvonralimab/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=QL1706> ;
  onco:status "approved" ;
  onco:tag "china", "nmpa-approved" ;
  onco:modality "Bifunctional antibody mixture: anti-PD-1 and anti-CTLA-4" ;
  onco:approval "CN 2024: Recurrent or metastatic cervical cancer after platinum chemotherapy" ;
  onco:cancers <https://onco.cc/cancers/cervical/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:companies <https://onco.cc/companies/qilu-pharmaceutical/> ;
  onco:trials <https://onco.cc/trials/nct06789796/>, <https://onco.cc/trials/nct07447570/>, <https://onco.cc/trials/nct07446387/> .